



Viral Hepatitis and Hepatocellular Carcinoma

Guest Editor:

Dr. Ruchi Shukla

Biosciences Institute, Newcastle
University, Newcastle upon Tyne
NE2 4HH, UK

Deadline for manuscript
submissions:

closed (31 August 2021)

Message from the Guest Editor

Dear Colleagues,

‘Viral hepatitis’ is a broad term to describe liver damage due to hepatitis virus (A, B, C, D and E) infection. Chronic hepatitis can lead to complications such as cirrhosis, liver failure and liver cancer, especially hepatocellular carcinoma (HCC).

Hepatitis B and C virus (HBV and HCV) infections are leading cause of HCC worldwide. A safe and effective vaccine against HBV is now available. There is no vaccine for HCV however, a major advance in the liver field in last 5 years has been the introduction of direct acting antivirals (DAAs) targeting HCV infection.

HCC is a stepwise process and involves a combination of genetic and epigenetic alterations. Hence, in this special issue I invite you to submit original articles, case reports or review articles to advance our existing knowledgebase regarding (i) viral hepatitis prevention or treatment, (ii) screening of chronic hepatitis patients to assess HCC development, (iii) molecular pathogenesis of viral hepatitis-related HCC development and (iv) novel treatment strategies for viral hepatitis-related HCC.

Dr. Ruchi Shukla

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com